These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33314489)

  • 21. BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
    Cifuentes-C L; Rivera-Herrera AL; Barreto G
    Colomb Med (Cali); 2019 Sep; 50(3):163-175. PubMed ID: 32284662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
    BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
    Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
    Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
    Chang S; Biswas K; Martin BK; Stauffer S; Sharan SK
    J Clin Invest; 2009 Oct; 119(10):3160-71. PubMed ID: 19770520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays.
    Biswas K; Lipton GB; Stauffer S; Sullivan T; Cleveland L; Southon E; Reid S; Magidson V; Iversen ES; Sharan SK
    NPJ Genom Med; 2020 Dec; 5(1):52. PubMed ID: 33293522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in classification of genetic variants in BRCA1 and BRCA2.
    Kast K; Wimberger P; Arnold N
    Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Recurrent Variants in
    Jiang Y; Tian T; Yu C; Zhou W; Yang J; Wang Y; Wen Y; Chen J; Dai J; Jin G; Ma H; Shen H; Hu Z
    Biomed Res Int; 2020; 2020():6739823. PubMed ID: 32879886
    [No Abstract]   [Full Text] [Related]  

  • 28. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.
    Abdallah N; Purrington KS; Tatineni S; Assad H; Petrucelli N; Simon MS
    Cancer Causes Control; 2023 Feb; 34(2):141-149. PubMed ID: 36370215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants.
    Sahu S; Sullivan TL; Mitrophanov AY; Galloux M; Nousome D; Southon E; Caylor D; Mishra AP; Evans CN; Clapp ME; Burkett S; Malys T; Chari R; Biswas K; Sharan SK
    PLoS Genet; 2023 Sep; 19(9):e1010940. PubMed ID: 37713444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
    Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
    Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
    Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
    Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
    Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
    Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population.
    Li D; Shi Y; Li A; Cao D; Su H; Yang H; Zhi Q; Yang Y; Lan Z; Zhou T; You X; Hu G
    Breast Cancer; 2020 Nov; 27(6):1158-1167. PubMed ID: 32566972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
    Cavallone L; Arcand SL; Maugard CM; Nolet S; Gaboury LA; Mes-Masson AM; Ghadirian P; Provencher D; Tonin PN
    Fam Cancer; 2010 Dec; 9(4):507-17. PubMed ID: 20694749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
    Toland AE; Andreassen PR
    J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
    Tram E; Savas S; Ozcelik H
    PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing.
    Liu PF; Zhuo ZL; Xie F; Wang S; Zhao XT
    Clin Chim Acta; 2021 May; 516():55-63. PubMed ID: 33476590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
    BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants.
    Park KS; Cho EY; Nam SJ; Ki CS; Kim JW
    Genet Med; 2016 Dec; 18(12):1250-1257. PubMed ID: 27124784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.